NGM Bio to Host Conference Call to Discuss Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH
May 23 2021 - 6:00PM
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) will host a conference
call and live webcast on Monday, May 24, 2021 at 8:30 a.m. ET (5:30
a.m. PT) to discuss topline results from the 24-week Phase 2b
ALPINE 2/3 study evaluating 0.3 mg, 1 mg and 3 mg doses of
aldafermin versus placebo in patients with non-alcoholic
steatohepatitis, or NASH, with stage 2 or 3 liver fibrosis.
Conference call and webcast details are as follows:
Live Conference CallDomestic
Callers: (844) 873-0551International Callers: (602)
563-8472Passcode: 9393531
Live and Archived
Webcast For
the live or archived webcast, please visit the “Investors &
Media” section of NGM’s website at https://ir.ngmbio.com/. The
webcast will be archived for 30 days.
Archived Conference Call Domestic
Callers: (855) 859-2056International Callers: (404)
537-3406Passcode: 9393531The archived conference call will be
available for 30 days.
About NGM Biopharmaceuticals, Inc.NGM is a
biopharmaceutical company focused on discovering and developing
novel therapeutics based on scientific understanding of key
biological pathways underlying liver and metabolic diseases,
retinal diseases and cancer. We leverage our biology-centric drug
discovery approach to uncover novel mechanisms of action and
generate proprietary insights that enable us to move rapidly into
proof-of-concept studies and deliver potential first-in-class
medicines to patients. At NGM, we aspire to operate one of the most
productive research and development engines in the
biopharmaceutical industry. Visit us at www.ngmbio.com for
more information.
Investor
Contact:Alex Schwartzir@ngmbio.com |
Media
Contact:Liz Melonemedia@ngmbio.com |
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Jun 2024 to Jul 2024
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Jul 2023 to Jul 2024